Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.